A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of
entospletinib. Participants with the following relapsed or refractory hematologic
malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic
leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL),
follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including
lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small lymphocytic
lymphoma [SLL], or marginal zone lymphoma [MZL]).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society